Efficacy of Pregabalin on Chronic Cough

Ottawa Hospital Research Institute

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Cough

Treatments: Drug: Pregabalin; Drug: Control-Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02482818

2011734-01H

Details and patient eligibility

About

The purpose of this study is to determine if Pregabalin, a medication used for the treatment of seizures and chronic pain, can be used to effectively treat people who suffer from non-asthmatic chronic cough (cough lasting over 8 weeks).

Full description

A significant number of patients have an impaired quality of life due to chronic cough that fails to respond to therapeutic efforts.

Research suggests that patients with chronic cough may have an oversensitive cough reflex. Reflexes are involuntary responses to nerve stimulation. Since standard cough medicines may not be helpful for treating the oversensitive cough reflex, treatment with neurologically acting agents has been investigated.

Existing work in treatment of cough of unknown etiology has focused on the use of Gabapentin, a compound that acts neurologically that is used in the treatment of epilepsy and pain. A similar drug, Pregabalin, may be a superior medication for this indication. Pregabalin is rapidly absorbed with peak blood concentrations within 1 hour, has an approximate bioavailability of 90%, and is 3 to 10 times more potent than Gabapentin and has no known pharmacokinetic drug interactions.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 84 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of non-asthmatic chronic cough defined as a cough experienced for a period of at least 8 weeks
• Negative methacholine challenge (within past year)
• Chest x-ray with absence of gross abnormality that could justify the cough or be a cause for the cough (within past 6 months)
• Male or female 18 years or older
• Willing and able to limit to 1 or less alcohol beverage per day (example: 360 ml of beer or 330 ml of cooler or 120 ml of wine)

Exclusion criteria

• Concurrent use of Gabapentin or Pregabalin for other indications (seizure disorder, chronic pain)
• History of allergy / intolerance or adverse effect with Gabapentin or Pregabalin.
• Concurrent use of central nervous system depressants (i.e. opioids or benzodiazepines)
• Not able to limit daily alcohol intake as recommended in the inclusion criteria
• Creatinine clearance < 60ml/min within past three months
• Current Smoker or has been quit less than 8 weeks
• Symptoms of post nasal drip
• History of gastroesophageal reflux. Only participants with untreated Gastroesophageal Reflux Disease (GERD) or less than 8 weeks of therapy will be excluded.
• Symptoms of upper airway cough syndrome
• ACE inhibitor use
• Allergy to citric acid
• Pregnant or nursing women
• History of angioedema or congestive heart failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

40 participants in 2 patient groups, including a placebo group

Control-Placebo

Placebo Comparator group

Description:

Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial. Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days). Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day. Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42.

Treatment:

Drug: Control-Placebo

Pregabalin

Experimental group

Description:

Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial. Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days). Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day. Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days. Forty two days after initial drug administration the Doctor will meet with subjects to follow up.

Treatment:

Drug: Pregabalin